Today's regulatory sweep returned no new cardiovascular drug approval, label change or safety communication. That is a real gap rather than an oversight: the sweep reads drug-regulator feeds, and much of what changes cardiology practice arrives as society guidance published as web documents, which it does not capture.
The substantive guidance this period is an American Heart Association scientific statement on caffeine and cardiovascular disease, which is worth knowing because patients ask about it constantly and the honest answer is more specific than most of us give. The statement describes an inverse J-shaped relationship between naturally occurring caffeinated products and blood pressure, habitual coffee associated with lower incident type 2 diabetes, and no clear relationship with blood lipids except that unfiltered coffee raises LDL. Randomised data in regular coffee drinkers showed caffeinated coffee reduced atrial fibrillation occurrence while increasing premature ventricular contractions.
The distinction that matters for clinic is between coffee and energy drinks. Evidence on moderate coffee is reassuring and in places favourable; data on the high doses in energy drinks are limited and generally suggest harm. Those are not interchangeable exposures, and advice that treats them as one substance is wrong in both directions.
- No new cardiovascular drug approval or safety action in today's sweep
- AHA statement: moderate coffee reassuring, energy drinks suggest harm
- Caffeinated coffee reduced AF occurrence but increased PVCs in randomised data
- Unfiltered coffee raises LDL; filtered does not
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free